Gabexate mesilate, a new synthetic serine protease inhibitor: a pilot clinical trial in valvular heart surgery.
OBJECTIVE
To assess the effects of gabexate mesilate ([GM], Foy, ONO Pharmaceutical Co, Osaka, Japan) on blood loss in cardiac valve replacement surgery and to establish whether GM reduces blood loss or transfusion requirements after this surgery.


METHODS
Randomized single-blind trial in 30 patients receiving either GM (2 mg/kg/h in a central venous catheter), or no GM, after heparin.


METHODS
Department of Anesthesia and Intensive Care, Cardiac Surgery, in a hospital in Italy.


METHODS
Consent patients.


METHODS
Cardiac valve replacement surgery.


RESULTS
Intraoperative and postoperative bleeding, blood transfusion, hemoglobin, and hematocrit were compared. In the GM group bleeding was reduced and no transfusions were required.


CONCLUSIONS
GM appears to play a useful role in reducing blood loss during extracorporeal circulation in cardiac surgery.
Parodi
F
F
Department of Anesthesia and Intensive Care, Ospedale Maggiore, Novara, Italy.
Cordero
G
G
De Gasperis
C
C
Minola
P
P
Dellora
C
C
Innocenti
P
P
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D016670:Gabexate / Q000627:therapeutic use*; D006350:Heart Valve Prosthesis; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects; D019106:Postoperative Hemorrhage / Q000517:prevention & control*; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D016037:Single-Blind Method
D000925:Anticoagulants; D015842:Serine Proteinase Inhibitors; D016670:Gabexate